An individualized immune prognostic signature in lung adenocarcinoma
Open Access
- 7 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Cell International
- Vol. 20 (1), 1-11
- https://doi.org/10.1186/s12935-020-01237-4
Abstract
Tumor immune infiltration is closely associated with clinical outcome in lung cancer. We aimed to develop an immune signature to improve the prognostic predictions of lung adenocarcinoma (LUAD). We applied “Cell type Identification by Estimating Relative Subsets of RNA Transcripts” method to quantify the fraction of 22 leukocyte cells from six public microarray datasets. Four datasets from GPL570 were treated as the training cohort and two datasets from GPL96 and GPL10379 as the validation cohorts. An immune risk score (IRS) based on leukocyte cell fraction was established by least absolute shrinkage and selection operator cox regression model. IRS consisting of 6 types of leukocytes was constructed in the training dataset. In the training cohort (520 patients), the IRS stratified patients into high-IRS group (215 patients) and low-IRS group (305 patients) with significant differences in overall survival (OS) (HR: 2.77, 95% CI 2.08–3.06). Multivariate analysis including age, gender, stage, IRS and tumor purity revealed the IRS to be an independent prognostic factor in all datasets (training: HR: 10.71, 95% CI 5.72–20.07; validation-1: HR 2.68, 95% CI 1.15–6.27; validation-2: HR 3.71, 95% CI 1.33–10.33); all p < 0.05). IRS was significantly positively correlated to the expression levels of PD1, PDL1, CTLA and LAG3 (all p < 0.001). When integrated with clinical characteristics including stage and age, the composite immune and clinical signature presented with improved prognostic accuracy than IRS (mean C-index 0.66 vs. 0.60). The proposed immune-clinical signature could predict OS in patients with LUAD effectively.Keywords
Funding Information
- National Natural Science Foundation of China (No. 81972172)
- Shanghai Municipal Health Commission (No. 2017BR026)
- Shanghai Education Development Foundation (No. 17SG23)
- Shanghai Hospital Development Center (No. SHDC12017X03)
This publication has 56 references indexed in Scilit:
- Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung AdenocarcinomaPLOS ONE, 2012
- A lung cancer molecular prognostic test ready for prime timeThe Lancet, 2012
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- The immune score as a new possible approach for the classification of cancerJournal of Translational Medicine, 2012
- Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancerCancer, 2011
- Mast Cells Mobilize Myeloid-Derived Suppressor Cells and Treg Cells in Tumor Microenvironment via IL-17 Pathway in Murine Hepatocarcinoma ModelPLOS ONE, 2010
- The New Lung Cancer Staging SystemSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2009
- Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung CancerClinical Cancer Research, 2008
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyNature Medicine, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005